Note: The following article synopsis was NOT provided by AAPC. It was created by Find-A-Code/innoviHealth.
Article Overview
This article covers a Government Accountability Office report on Medicare chemotherapy drug and administration fees and the response from the American Society for Clinical Oncology. It is relevant to oncology billing professionals, physician practices, and reimbursement analysts who track Medicare payment policy, drug acquisition costs, and practice expense impacts.
Why This Topic Matters
The piece highlights a payer-policy dispute that could affect oncology reimbursement planning and the interpretation of Medicare cost studies for physician practices.
What You Will Learn
What the GAO report examined in relation to oncology drug payments
How ASCO responded to the report's findings
Why acquisition cost variation matters in payment analysis
How practice expense payment changes may affect oncology compared with other specialties
Who Should Read This
Oncology coders
Medical billers
Physician practice managers
Reimbursement analysts
Healthcare policy professionals
Subscribe or sign in to view the full article.
Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.
Fully searchable archives - over 5250 articles
ALL years/issues back to 2003 organized by year and issue
Codes mentioned in articles are linked to Code Information pages
Code Information pages link back to related articles
This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.
Related Articles
Articles are listed in order of calculated relevance.
Quick, Current, Complete - www.findacode.com